AIM, the International Association for Mutual Benefit Societies representing statutory and complementary health insurance funds and mutuals in 16 European countries welcomes the Biotech Act proposed by the European Commission on December 16th, 2025.

Europe’s competitiveness in biotechnology harnessing the excellence and quality of research and industry is of utmost importance. At the same time, our members based on solidarity, not for profit and democracy underline the need to put the improvement of patient’s lives in the centre of the ambition of the European Commission in this respect. The patient should be the beneficiary of the innovation and should enjoy the highest quality and safety standards. Biotechnology should thus be affordable, available and accessible for all without inequalities.